Top Page
Sanofi
(NASDAQ:SNY)
Sanofi (SNY) vs. SPDR S&P 500 ETF (SPY)
Sanofi Business Overview & Revenue Model
Sanofi Earnings Call Summary
Sanofi Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 46.72B | 44.29B | 41.62B | 40.56B | 39.17B |
| Gross Profit | 33.79B | 31.08B | 28.99B | 28.68B | 26.92B |
| EBITDA | 12.68B | 11.03B | 11.39B | 13.51B | 11.54B |
| Net Income | 7.81B | 5.56B | 5.40B | 8.37B | 6.22B |
Balance Sheet | |||||
| Total Assets | 126.81B | 132.80B | 126.46B | 126.72B | 120.24B |
| Cash, Cash Equivalents and Short-Term Investments | 7.66B | 7.93B | 8.71B | 12.74B | 10.10B |
| Total Debt | 21.79B | 17.91B | 18.70B | 21.21B | 22.41B |
| Total Liabilities | 55.10B | 54.94B | 52.11B | 51.57B | 51.21B |
| Stockholders Equity | 71.38B | 77.51B | 74.04B | 74.78B | 68.68B |
Cash Flow | |||||
| Free Cash Flow | 8.89B | 5.89B | 8.64B | 8.32B | 8.48B |
| Operating Cash Flow | 10.75B | 9.08B | 10.26B | 10.53B | 10.52B |
| Investing Cash Flow | -2.35B | -4.41B | -6.20B | -2.08B | -7.30B |
| Financing Cash Flow | -8.21B | -5.76B | -8.05B | -5.82B | -7.06B |
Sanofi Technical Analysis
Sanofi Risk Analysis
Sanofi Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $300.17B | 17.01 | 36.91% | 3.12% | 1.59% | 58.02% | |
77 Outperform | $317.37B | 23.26 | 31.14% | 2.87% | 11.53% | -15.21% | |
74 Outperform | $186.25B | 21.97 | 40.49% | 2.52% | 2.76% | 6407.19% | |
71 Outperform | $126.95B | 18.03 | 40.53% | 4.84% | 1.26% | ― | |
69 Neutral | $115.34B | 20.23 | 6.76% | 4.58% | -9.32% | 120.62% | |
64 Neutral | $155.01B | 20.39 | 8.87% | 6.65% | 4.44% | 128.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sanofi Corporate Events
On January 29, 2026, Sanofi reported that in 2025 it delivered strong top- and bottom-line growth, with full-year net sales rising 9.9% at constant exchange rates to €43.6 billion and business EPS advancing 15.0% to €7.83, indicating profitability improving faster than revenue. Fourth-quarter 2025 sales grew 13.3% at constant exchange rates to €11.3 billion and business EPS climbed 26.7% to €1.53, driven by a 49.4% surge in revenue from new pharma launches to €1.1 billion—led by Ayvakit and ALTUVIIIO—and a 32.2% increase in Dupixent sales to €4.2 billion, while vaccines declined modestly and higher R&D and SG&A spending supported the launch engine and pipeline. The company highlighted robust pipeline momentum with ten regulatory approvals across immunology and rare diseases, multiple positive phase 3 readouts, and new late-stage starts, and it reinforced its capital allocation strategy through the announced Dynavax acquisition, completion of the Vicebio acquisition, a €5 billion share buyback, and a proposed 5.1% dividend increase to €4.12 per share. Sanofi also underscored strategic moves to shape its operating environment, including an agreement with the U.S. government to reduce medicine costs while backing innovation and leadership in an industry working group on biopharma life-cycle assessment, and it guided for 2026 sales to grow at a high single-digit rate at constant exchange rates with business EPS rising slightly faster, supported in part by a planned €1 billion share buyback program, signaling continued profitable growth and confidence in its mid-term outlook.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On January 23, 2026, Sanofi reported new phase 3 data showing that its investigational monoclonal antibody amlitelimab, which targets OX40-ligand without depleting T cells, delivered a strong efficacy and safety profile in patients aged 12 and older with moderate-to-severe atopic dermatitis. In the SHORE phase 3 trial, amlitelimab given every four or twelve weeks alongside topical therapies met all primary and key secondary endpoints at Week 24 across both US and EU statistical frameworks, with efficacy increasing over time and some patients improving as early as Week 2. In the COAST 2 phase 3 monotherapy study, amlitelimab met the primary vIGA-AD 0/1 endpoint for the US estimand and confirmed the potential for dosing every 12 weeks from treatment initiation, although it did not reach statistical significance on co-primary endpoints under the EU estimand, meaning some secondary outcomes are reported with only nominal significance. Across both studies, amlitelimab’s safety profile was comparable to placebo with similar rates of treatment-emergent and serious adverse events, and a separate phase 2 ATLANTIS trial showed continued efficacy improvements through Week 52, reinforcing OX40-ligand as a promising new mechanism in atopic dermatitis; based on the combined evidence, Sanofi plans to advance amlitelimab to global regulatory submissions, potentially strengthening its position in the competitive immunology market if approved.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On January 12, 2026, the European Commission approved Sanofi’s Teizeild (teplizumab) as the first disease‑modifying therapy in the European Union to delay the onset of stage 3 type 1 diabetes in adults and children aged eight years and older with stage 2 disease. The decision, based on the phase 2 TN-10 trial, showed Teizeild could delay progression to clinical type 1 diabetes by a median of two years versus placebo and nearly double the proportion of patients remaining in stage 2, with a safety profile mainly characterized by transient lymphopenia and rash. Already marketed under the name Tzield in the US and several other key markets, the EU approval strengthens Sanofi’s position in autoimmune diabetes, expands its global footprint in disease‑modifying therapies, and underscores a strategic choice to focus Teizeild on delaying disease progression rather than pursuing, for now, a second indication in newly diagnosed stage 3 type 1 diabetes.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On January 5, 2026, Sanofi announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics license application for its type 1 diabetes drug Tzield (teplizumab-mzwv), seeking to extend its use from patients aged eight and older to children as young as one year with stage 2 type 1 diabetes, with a target decision date of April 29, 2026. The filing, based on interim one-year data from the ongoing PETITE-T1D phase 4 study in children under eight, underscores Tzield’s role as the first and only disease-modifying therapy for autoimmune type 1 diabetes and, if approved, would significantly strengthen Sanofi’s position in diabetes immunotherapy by opening access to a younger pediatric population and potentially reshaping early-stage disease management for patients and caregivers globally.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 24, 2025, Sanofi announced an agreement to acquire Dynavax Technologies Corporation, a commercial-stage vaccines company, in a cash transaction valuing Dynavax’s equity at about $2.2 billion, as it looks to strengthen its position in adult immunization. The deal will add Dynavax’s marketed adult hepatitis B vaccine HEPLISAV-B, noted for its faster two-dose, one-month regimen, and a phase 1/2 shingles vaccine candidate Z-1018, along with additional vaccine pipeline projects; the Dynavax board unanimously approved the transaction, which Sanofi will fund with cash and which is expected to close in the first quarter of 2026, subject to customary regulatory and tender offer conditions, with no impact anticipated on Sanofi’s 2025 financial guidance and potential long-term benefits for its vaccines franchise and adult vaccination market reach.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 24, 2025, Sanofi announced that the US Food and Drug Administration issued a complete response letter for its new drug application for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis in adults, marking a sharp reversal from prior regulatory interactions that had led to breakthrough therapy designation for the candidate. The company expressed disappointment with the FDA’s decision but said it remains committed to working with the agency to find a path forward, while highlighting that tolebrutinib already holds a provisional approval in the United Arab Emirates and is under review in the European Union and other markets; Sanofi is also conducting an IFRS impairment test on the intangible asset value of tolebrutinib, with results due alongside its fourth-quarter and full-year 2025 earnings, although it expects no impact on business net income, earnings per share, or its 2025 financial guidance.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 23, 2025, the European Commission approved Sanofi’s Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor indicated for adult immune thrombocytopenia (ITP) patients who are refractory to other treatments, marking a significant expansion of Sanofi’s rare disease portfolio in a complex, underserved segment. The once-daily oral therapy, already approved in the US and UAE and supported by positive phase 3 LUNA 3 data showing rapid, durable platelet responses and quality-of-life improvements versus placebo, strengthens Sanofi’s positioning in immunology and rare diseases and underscores the strategic value of its BTK and TAILORED COVALENCY® platform, with additional rare indications under investigation that could further broaden its specialty care franchise.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 17, 2025, Sanofi announced that the European Medicines Agency granted orphan designation to efdoralprin alfa (SAR447537), its investigational recombinant human alpha-1 antitrypsin-Fc fusion protein, for the potential treatment of alpha-1 antitrypsin deficiency (AATD) related emphysema, a rare and debilitating respiratory disease. The candidate recently showed superiority to a plasma-derived standard-of-care therapy in a global Phase 2 head-to-head trial, meeting all primary and key secondary endpoints with dosing every three or four weeks, adding to prior U.S. fast track and orphan drug designations and reinforcing Sanofi’s strategy of building a differentiated rare-disease portfolio in an indication where no new therapies have been introduced since 1987 and where underdiagnosis remains high.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 19, 2025, Sanofi announced it had reached a voluntary agreement with the Trump Administration to cut US medicine costs while reinforcing the country’s role in biopharmaceutical innovation and manufacturing. The three-year framework gives Sanofi a Section 232 tariff exemption on its US imports and commits the company to align Medicaid prices for several wholly owned medicines with those in other high‑income countries, implying average price reductions of around 61% for certain diabetes, cardiovascular, neurological and oncology treatments, and to offer US patients direct access to selected drugs, including insulins, at discounts nearing 70% via TrumpRx.gov and other direct‑to‑patient platforms. Sanofi will also pursue a more ‘balanced’ pricing strategy in other wealthy markets and build on a previously announced US$20 billion investment plan to upgrade and expand manufacturing capacity, with management stressing that the accord supports its Take the Lead growth strategy and does not alter its financial outlook over the agreement period, signaling a bid to protect long-term innovation and US industrial presence while responding to political and public pressure on drug prices.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Sanofi announced on December 15, 2025, that the U.S. regulatory review process for tolebrutinib, a treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is expected to extend beyond the initial target action date of December 28, 2025. The company is in ongoing discussions with the FDA and anticipates further guidance by the end of the first quarter of 2026. Sanofi has submitted an expanded access protocol for tolebrutinib, emphasizing its commitment to providing access to this investigational therapy, which targets smoldering neuroinflammation, a key driver of disability progression in multiple sclerosis.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its capabilities in vaccine design and development. This acquisition introduces an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), expanding Sanofi’s respiratory vaccine portfolio with a non-mRNA option. Additionally, Sanofi received approval in China for its drugs Qfitlia and Cablivi, which are intended to expand care for rare diseases, marking a significant step in broadening its market reach and strengthening its position in the global pharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved Dupixent (dupilumab) as the first targeted medicine in over a decade for treating moderate-to-severe chronic spontaneous urticaria (CSU) in the EU. This approval, based on phase 3 studies, marks a significant advancement for patients with CSU, providing a new treatment option that significantly reduces symptoms like itch and hives, which were previously inadequately controlled by standard antihistamines. The approval is expected to enhance Sanofi’s position in the immunology market and offer a new therapeutic option for the estimated 270,000 individuals in the EU suffering from CSU.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November 7, 2025, Sanofi, in collaboration with Regeneron, revealed that their drug Dupixent met all primary and secondary endpoints in a pivotal phase 3 study for allergic fungal rhinosinusitis (AFRS), leading to the acceptance of a supplemental biologics license application for FDA priority review. This marks a potential new indication for Dupixent, which could become the first treatment specifically approved for AFRS. Additionally, on November 14, 2025, Sanofi’s drug Teizeild received a recommendation for EU approval for patients with stage 2 type 1 diabetes. These developments highlight Sanofi’s ongoing commitment to expanding its treatment portfolio and enhancing its market position in the pharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On November 3, 2025, Sanofi announced the issuance of $3 billion in notes, including floating and fixed rate notes due in 2027, 2028, and 2032. This strategic financial move is expected to enhance Sanofi’s capital structure and support its long-term growth objectives, potentially impacting its market position and providing liquidity for future investments.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On October 22, 2025, Sanofi announced that its investigational drug, efdoralprin alfa, met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. The drug showed superiority over standard plasma-derived therapy, offering less frequent dosing and maintaining higher functional AAT levels, which could significantly improve treatment convenience for patients. These results highlight the potential of efdoralprin alfa as a restorative recombinant therapy, reinforcing Sanofi’s commitment to addressing unmet medical needs in rare and respiratory conditions. The study’s positive outcomes may enhance Sanofi’s industry positioning and offer new hope to stakeholders in the AATD community.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.